ALMS1 — Alstrom syndrome 1

The ALMS1 gene provides the body with instructions for making a protein that is found in almost every cell. This protein acts like a crucial piece of scaffolding or a transport manager within the cell's "antenna," known as the primary cilium. These antennae are vital for cells to sense their environment and communicate with each other. The ALMS1 protein helps organize the cell's internal structure and ensures that important materials are moved to the right places, especially in specialized cells like those in the eyes, ears, and organs that manage metabolism. When the ALMS1 gene is mutated, it produces a shortened, non-working version of the protein, or sometimes no protein at all. Without functional ALMS1, the cellular antennae cannot work properly. This breakdown in cellular communication and transport leads to Alström syndrome, a rare and complex condition. For patients, this means a progressive loss of vision and hearing starting in childhood. It also causes severe metabolic issues, including rapid weight gain leading to obesity, and a high risk of developing type 2 diabetes at a young age. Additionally, the lack of this protein can cause serious problems with the heart, kidneys, and liver over time. Alström syndrome is an autosomal recessive genetic condition. This means that a person must inherit two mutated copies of the ALMS1 gene—one from each parent—to develop the disease. The parents, who each carry one mutated copy and one normal copy, are called carriers. Carriers typically do not show any symptoms of the syndrome. When two carriers have a child, there is a 25% chance with each pregnancy that the child will inherit both mutated genes and have Alström syndrome. Understanding this inheritance pattern is important for families when considering genetic testing and family planning.

Gene description: ALMS1 encodes a centrosomal protein involved in ciliary function, cell cycle regulation, and intracellular trafficking.

Patient and family guide: The ALMS1 gene provides the body with instructions for making a protein that is found in almost every cell. This protein acts like a crucial piece of scaffolding or a transport manager within the cell's "antenna," known as the primary cilium. These antennae are vital for cells to sense their environment and communicate with each other. The ALMS1 protein helps organize the cell's internal structure and ensures that important materials are moved to the right places, especially in specialized cells like those in the eyes, ears, and organs that manage metabolism. When the ALMS1 gene is mutated, it produces a shortened, non-working version of the protein, or sometimes no protein at all. Without functional ALMS1, the cellular antennae cannot work properly. This breakdown in cellular communication and transport leads to Alström syndrome, a rare and complex condition. For patients, this means a progressive loss of vision and hearing starting in childhood. It also causes severe metabolic issues, including rapid weight gain leading to obesity, and a high risk of developing type 2 diabetes at a young age. Additionally, the lack of this protein can cause serious problems with the heart, kidneys, and liver over time. Alström syndrome is an autosomal recessive genetic condition. This means that a person must inherit two mutated copies of the ALMS1 gene—one from each parent—to develop the disease. The parents, who each carry one mutated copy and one normal copy, are called carriers. Carriers typically do not show any symptoms of the syndrome. When two carriers have a child, there is a 25% chance with each pregnancy that the child will inherit both mutated genes and have Alström syndrome. Understanding this inheritance pattern is important for families when considering genetic testing and family planning.

Gene function: ALMS1 is a large protein localized to centrosomes and basal bodies, playing a critical role in ciliary function and maintenance. Its involvement in Alström syndrome, which includes progressive cone-rod dystrophy, suggests its importance in photoreceptor health. ALMS1 likely contributes to the structural integrity and signaling within photoreceptor cilia, essential for phototransduction and cell survival.

Protein structure: The ALMS1 gene encodes a massive protein consisting of 4,169 amino acids, with an estimated molecular weight of approximately 460 kDa. Despite its large size, the ALMS1 protein lacks well-defined, classical catalytic domains, making its precise biochemical function challenging to elucidate. The protein structure is characterized by a large tandem-repeat domain and several regions of low complexity. A notable feature is the presence of an ALMS motif, a conserved region near the C-terminus that is thought to be critical for its localization and function. The protein is highly hydrophilic and contains numerous potential sites for post-translational modifications, including phosphorylation, which may regulate its activity and interactions. Structurally, ALMS1 is a core component of the centrosome and the basal body of primary cilia. It localizes specifically to the proximal ends of the mother and daughter centrioles. The protein is believed to function as a structural scaffold or a docking site, facilitating the assembly of multi-protein complexes essential for microtubule organization and ciliary function. It interacts with various other centrosomal and ciliary proteins, playing a crucial role in the cohesion of the centrosome and the structural integrity of the basal body. The large size and complex interactome of ALMS1 suggest it acts as a central hub coordinating multiple cellular processes, including intracellular trafficking and signal transduction.

Molecular function: The ALMS1 gene encodes a large, complex protein that plays a critical role in the structure and function of centrosomes and primary cilia. At the cellular level, ALMS1 localizes specifically to the proximal ends of centrioles and basal bodies, which are the microtubule-based organizing centers essential for cell division and ciliogenesis. The primary cilium acts as a sensory antenna for the cell, coordinating various signal transduction pathways. ALMS1 is implicated in the maintenance of these ciliary structures and is thought to be involved in intracellular trafficking, particularly the transport of proteins and lipids into and out of the cilium via intraflagellar transport (IFT) mechanisms. Beyond its structural role, ALMS1 is involved in several key biochemical and signaling pathways. It has been linked to the regulation of the TGF-β signaling pathway, which is crucial for cell growth, differentiation, and extracellular matrix production. Disruption of ALMS1 alters TGF-β signaling, potentially contributing to the widespread tissue fibrosis observed in Alström syndrome. Furthermore, ALMS1 plays a significant role in metabolic regulation, particularly in adipocyte differentiation and insulin signaling. Loss of ALMS1 function impairs the translocation of the GLUT4 glucose transporter to the cell membrane, leading to severe insulin resistance. In highly specialized sensory cells, such as the photoreceptors of the retina and the hair cells of the inner ear, ALMS1 is vital for the maintenance of the specialized ciliary structures required for sensory transduction. In photoreceptors, the connecting cilium is essential for the massive daily transport of opsins and other proteins to the outer segment. ALMS1 deficiency disrupts this transport, leading to the progressive degeneration of photoreceptor cells (cone-rod dystrophy). Similarly, in the inner ear, the loss of ALMS1 affects the structural integrity and function of the ciliated hair cells, resulting in sensorineural hearing loss.

Expression pattern: The ALMS1 gene is widely expressed across a broad range of tissues, reflecting its fundamental role in cellular biology and the multi-systemic nature of Alström syndrome. Expression is detected at low to moderate levels in almost all organs, including the brain, heart, skeletal muscle, pancreas, kidney, liver, lungs, and adipose tissue. Within the eye, ALMS1 is prominently expressed in the retina, specifically localizing to the photoreceptor cells, where it is essential for the maintenance and function of the connecting cilium and outer segment. Similarly, in the inner ear, the protein is expressed in the ciliated hair cells of the cochlea, underscoring its importance in auditory sensory transduction. At the cellular level, the ALMS1 protein is ubiquitously localized to the centrosomes and the basal bodies of primary cilia. This specific subcellular localization is consistent across various cell types, from fibroblasts and epithelial cells to highly specialized sensory neurons. The widespread expression pattern and consistent localization to ciliary structures support the hypothesis that ALMS1 is a core component of the ciliary machinery, required for the proper assembly, maintenance, or function of primary cilia throughout the body. The ubiquitous nature of its expression explains why mutations in ALMS1 lead to the diverse and widespread clinical features observed in Alström syndrome.

Mutation spectrum: The mutation spectrum of the ALMS1 gene is characterized by a wide array of pathogenic variants, with over 300 distinct mutations identified to date. The vast majority of these—approximately 96%—are nonsense or frameshift mutations (insertions or deletions) that introduce premature stop codons, leading to the production of a truncated, non-functional protein or resulting in nonsense-mediated mRNA decay. These truncating mutations are distributed throughout the gene but are notably concentrated in the largest exons, particularly exons 8, 10, and 16, which together account for a significant portion of the coding sequence. Exon 8 alone harbors nearly half of all known mutations. In addition to the predominant truncating mutations, a smaller number of missense mutations, splice-site variants, and large genomic deletions have been reported. While many mutations are private or restricted to specific families, certain founder mutations have been identified in isolated populations or specific ethnic groups, leading to a higher local prevalence of Alström syndrome. The extensive allelic heterogeneity and the high frequency of novel mutations complicate molecular diagnosis, necessitating comprehensive sequencing approaches to identify the causative variants in affected individuals.

Pathogenic variants: 1. p.Arg2721* (c.8161C>T) - A common nonsense mutation located in exon 10, resulting in premature protein truncation and associated with the classic multi-systemic features of Alström syndrome. 2. p.Ser2536* (c.7607C>G) - Another frequently observed nonsense mutation in exon 10, leading to a loss of functional ALMS1 protein and severe metabolic and sensory deficits. 3. p.Gln2051* (c.6151C>T) - A truncating mutation situated in the large exon 8, which is a hotspot for pathogenic variants, causing the typical Alström syndrome phenotype. 4. c.10775delC (p.Pro3592Leufs*12) - A frameshift mutation in exon 16 caused by a single nucleotide deletion, resulting in a premature stop codon and complete loss of protein function. 5. c.11449C>T (p.Arg3817*) - A nonsense mutation in exon 16 that truncates the ALMS1 protein near its C-terminus, consistently linked to the development of early-onset obesity, retinal dystrophy, and insulin resistance.

Clinical significance: Mutations in the ALMS1 gene are the primary cause of Alström syndrome, a rare autosomal recessive disorder characterized by a complex and progressive multi-systemic phenotype. The clinical manifestations typically begin in infancy with visual disturbances, specifically cone-rod dystrophy, which presents as nystagmus and extreme photophobia. This early-onset retinal degeneration leads to progressive vision loss, often resulting in complete blindness by the second decade of life. Concurrently, many affected individuals develop sensorineural hearing loss, which usually becomes apparent in the first decade and progresses to moderate or severe impairment. Beyond sensory deficits, Alström syndrome is profoundly characterized by severe metabolic disturbances. Children typically exhibit rapid weight gain leading to truncal obesity within the first few years of life. This is closely followed by the development of severe insulin resistance, hyperinsulinemia, and early-onset type 2 diabetes mellitus. The metabolic syndrome is further complicated by hypertriglyceridemia, which can precipitate life-threatening pancreatitis. Additionally, a significant proportion of patients experience cardiac complications, most notably infantile-onset dilated cardiomyopathy, which can be transient but severe, or a later-onset restrictive cardiomyopathy associated with myocardial fibrosis. The clinical spectrum of Alström syndrome also encompasses progressive dysfunction of other major organs. Hepatic steatosis and fibrosis are common, potentially leading to liver failure. Renal involvement is characterized by slowly progressive chronic kidney disease, which can advance to end-stage renal disease in adolescence or adulthood. Other features include short stature in adulthood, hypogonadism, urologic dysfunction, and widespread tissue fibrosis. The severity and age of onset of these clinical features exhibit considerable variability, even among siblings with identical ALMS1 mutations, suggesting the influence of genetic modifiers or environmental factors.

Inheritance: Autosomal Recessive

Chromosomal location: 2p13.1

Genotype-phenotype correlations: Establishing clear genotype-phenotype correlations in Alström syndrome has proven challenging due to the high degree of clinical variability observed among patients, even those harboring identical ALMS1 mutations. The vast majority of pathogenic variants are nonsense or frameshift mutations that result in premature protein truncation, leading to a complete loss of functional ALMS1 protein. Consequently, the core features of the syndrome—such as cone-rod dystrophy, obesity, and insulin resistance—are consistently present across different mutation types. However, the age of onset, severity, and progression of specific complications, such as cardiomyopathy or renal failure, can vary significantly. Some studies have suggested potential, albeit weak, correlations between the location of the mutation within the ALMS1 gene and the severity of certain phenotypes. For instance, mutations occurring in specific exons might be associated with a higher risk of early-onset cardiomyopathy or a more rapid progression of renal disease. Additionally, the presence of residual ALMS1 gene expression or alternative splicing might contribute to milder phenotypic presentations in some individuals. Despite these observations, the lack of robust genotype-phenotype correlations indicates that other factors, such as genetic modifiers, epigenetic regulation, and environmental influences, play a substantial role in determining the clinical trajectory of Alström syndrome.

Research and therapeutic approaches: Currently, there are no approved, curative therapies specifically targeting the underlying genetic defect in Alström syndrome. Medical management is primarily symptomatic and supportive, requiring a multidisciplinary approach to address the complex multi-organ involvement. Treatment focuses on managing the metabolic complications, such as using insulin-sensitizing agents (e.g., metformin) and lipid-lowering drugs to control type 2 diabetes and hypertriglyceridemia. Cardiac failure, renal dysfunction, and hepatic disease are managed according to standard clinical guidelines. For the sensory deficits, early intervention with low-vision aids, educational support, and hearing aids or cochlear implants are essential to improve the quality of life for affected individuals. Research into targeted therapeutic approaches for Alström syndrome is ongoing, with several promising strategies in the pipeline. Gene therapy holds significant potential, particularly for addressing the retinal degeneration. Preclinical studies using adeno-associated viral (AAV) vectors to deliver functional copies of the ALMS1 gene or related therapeutic genes have shown promise in animal models, aiming to halt or slow the progression of cone-rod dystrophy. However, the large size of the ALMS1 gene presents a challenge for standard AAV packaging, necessitating innovative approaches such as dual-vector systems or the use of smaller, functional gene fragments. In addition to gene replacement, other investigational strategies are being explored. For the large proportion of patients with nonsense mutations, small-molecule read-through agents (such as PTC124/ataluren) are being investigated for their ability to suppress premature stop codons and restore the production of full-length ALMS1 protein. Furthermore, therapies targeting the downstream pathways affected by ALMS1 deficiency, such as anti-fibrotic agents to combat multi-organ fibrosis or novel metabolic modulators, are under consideration. While these targeted therapies are still in the preclinical or early clinical stages, they represent a critical frontier in the effort to develop disease-modifying treatments for Alström syndrome.

Diagnostic testing: Diagnostic testing for Alström syndrome primarily involves molecular genetic analysis to identify pathogenic variants in the ALMS1 gene. Given the large size of the gene and the wide distribution of mutations, next-generation sequencing (NGS) approaches, such as targeted gene panels that include ALMS1 or whole exome sequencing (WES), are the preferred methods. These technologies allow for the comprehensive screening of all 23 exons and splice site junctions. In some cases, targeted mutation analysis may be used if specific familial variants are known. Early diagnosis is crucial for the proactive management of the multi-systemic complications associated with the syndrome. Genetic counseling is an essential component of the diagnostic process for families affected by Alström syndrome. Because the condition is inherited in an autosomal recessive manner, parents of an affected child are obligate carriers and have a 25% chance of having another affected child in each subsequent pregnancy. Carrier testing for at-risk relatives and prenatal diagnosis for pregnancies at increased risk are possible if the pathogenic variants have been identified in an affected family member. Counselors must address the complex and progressive nature of the disease, providing support and guidance on the multidisciplinary medical care required, including regular monitoring for cardiac, metabolic, renal, and sensory complications.

Animal models: Animal models have been instrumental in elucidating the function of ALMS1 and the pathogenesis of Alström syndrome. Mouse models, including both spontaneous mutants (such as the foz/foz mouse) and targeted knockouts, faithfully recapitulate many of the metabolic and sensory features of the human disease. These mice develop early-onset obesity, hyperinsulinemia, and progressive retinal degeneration, providing a robust platform for studying the metabolic syndrome and cone-rod dystrophy associated with ALMS1 deficiency. Studies in these models have highlighted the role of ALMS1 in ciliary function, intracellular trafficking, and adipocyte differentiation, demonstrating that loss of the protein disrupts energy homeostasis and sensory organelle maintenance. In addition to murine models, zebrafish (Danio rerio) have emerged as a valuable tool for studying ALMS1. Genomic knockout of alms1 in zebrafish recapitulates key aspects of Alström syndrome, including metabolic disturbances and sensory defects. The optical transparency of zebrafish embryos allows for real-time in vivo imaging of ciliary dynamics and cellular processes, offering unique insights into the developmental and cellular consequences of ALMS1 depletion. These diverse animal models continue to be essential for testing potential therapeutic interventions, including gene therapy and small-molecule approaches, aimed at mitigating the multi-systemic effects of Alström syndrome.

Population genetics: Alström syndrome is an exceedingly rare genetic disorder, with an estimated prevalence of approximately 1 in 1,000,000 individuals in the general population. Consequently, the carrier frequency for pathogenic ALMS1 mutations is very low globally. However, the prevalence can be significantly higher in certain isolated populations or specific ethnic groups due to founder effects and consanguinity. In these communities, specific ALMS1 mutations may be more common, leading to a higher incidence of the syndrome. Despite its rarity, the widespread distribution of over 300 different mutations indicates that Alström syndrome occurs across diverse ethnic backgrounds worldwide, though the exact carrier rates in most populations remain undefined.

Selected references: 1. Hearn T, et al. ALMS1 and Alström syndrome: a recessive form of metabolic, neurosensory and cardiac deficits. J Mol Med (Berl), 2019. PMID: 30421101 2. Marshall JD, et al. Alström Syndrome: Genetics and Clinical Overview. Curr Genomics, 2011. PMID: 22043170 3. Marshall JD, et al. Alström Syndrome: Mutation spectrum of ALMS1. Hum Mutat, 2015. PMID: 25846608 4. Li G, et al. A role for Alström syndrome protein, alms1, in kidney ciliogenesis and cellular quiescence. PLoS Genet, 2007. PMID: 17206865 5. Wang C, et al. Novel Mutations of the ALMS1 Gene in Patients with Alström Syndrome. Front Genet, 2021. PMID: 35003215 6. Bea-Mascato B, et al. Prevalent ALMS1 Pathogenic Variants in Spanish Alström Syndrome Patients. Genes (Basel), 2021. PMID: 33671353 7. Paisey RB, et al. Alström Syndrome. GeneReviews, 2003 (Updated 2019). PMID: 20301444